ANS05
/ Avistone Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2026
ANS05, a Novel Irreversible Brain-penetrant HER2 TKI, Targets Clinically Relevant HER2 Alterations and Demonstrates Potent Broad-Spectrum Preclinical Activity
(EORTC-NCI-AACR 2026)
- "Abstract will be available as of 4 November (with consent of the author)"
Preclinical • Oncology • HER-2
1 to 1
Of
1
Go to page
1